Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
about
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.Oncogene-addicted non-small cell lung cancer and immunotherapy.Durvalumab in NSCLC: latest evidence and clinical potentialPembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
P2860
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Targeting the PD-1/PD-L1 Immun ...... ed Non-Small-Cell Lung Cancer.
@en
type
label
Targeting the PD-1/PD-L1 Immun ...... ed Non-Small-Cell Lung Cancer.
@en
prefLabel
Targeting the PD-1/PD-L1 Immun ...... ed Non-Small-Cell Lung Cancer.
@en
P2093
P2860
P50
P1433
P1476
Targeting the PD-1/PD-L1 Immun ...... ted Non-Small-Cell Lung Cancer
@en
P2093
Gilles Robinet
Jacques Margery
Jean-Bernard Auliac
Nicolas Paleiron
Radj Gervais
P2860
P2888
P304
P356
10.1007/S11523-017-0510-9
P577
2017-10-01T00:00:00Z
P6179
1086072429